Basal Cell Carcinoma
Conditions
Keywords
basal cell carcinoma, curettage, Imiquimod, treatment
Brief summary
The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone.
Detailed description
Basal Cell Carcinomas (BCC) are the commonest form of skin cancer in the white population. The face is where they most frequently occur and the nodular BCCs are the commonest type. Curettage and cautery/electrodessication (C&C) has been an established way of management of nodular BCCs for years, being a simple surgical procedure readily performed in outpatient clinics with good aesthetic results and high cure rates. The purpose of this study is to determine recurrence rates of nodular BCCs on the face removed with C&C followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with C&C alone. Imiquimod is an immune response modifier with anti-tumour effects already licensed for the treatment of superficial BCCs in the UK.
Interventions
DRUGImiquimod cream
PROCEDUREcurettage and cautery
Sponsors
NHS Greater Glasgow and Clyde
Glasgow Western Infirmary
University of Glasgow
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
49 Years to 89 Years
Healthy volunteers
Yes
Inclusion criteria
* Well-defined primary, not previously treated nodulo-cystic BCC * Size of the lesions: ≤ 1cm diameter * Facial lesions * Patient compliance competent * Patient physically able to apply the treatment (cream)
Exclusion criteria
* Recurrent lesions * Superficial, morphoeic or pigmented BCC * Lesions close to vital structures; i.e. where C&C is not considered a standard treatment (eyelids, inner canthus, free borders) * Lesions within 1 cm of the eyelids, nose, lips and hairline * Immunosuppressed patients * Women in childbearing age, pregnancy and breast-feeding * Ages \<50 or \>90 * Patients compliance incompetent * Patients physically incapable to apply the treatment (cream) * Patients with Gorlin Syndrome (nevoid Basal Cell Carcinoma syndrome)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Basal Cell Carcinoma recurrence rates in 3 years | — |
Countries
United Kingdom
Contacts
Primary ContactRobert Herd, Consultant Dermatologist
Outcome results
None listed